Invention Grant
- Patent Title: Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity
-
Application No.: US17047877Application Date: 2019-04-10
-
Publication No.: US11358973B2Publication Date: 2022-06-14
- Inventor: Yihan Wang , Jiuyang Zhao , Yixin Ai
- Applicant: Shenzhen TargetRx, Inc.
- Applicant Address: CN Guangdong
- Assignee: Shenzhen TargetRx, Inc.
- Current Assignee: Shenzhen TargetRx, Inc.
- Current Assignee Address: CN Guangdong
- Agency: Wolf, Greenfield & Sacks, P.C.
- Priority: CN201810337944.6 20180416,CN201810338480.0 20180416
- International Application: PCT/CN2019/082051 WO 20190410
- International Announcement: WO2019/201131 WO 20191024
- Main IPC: C07D471/22
- IPC: C07D471/22 ; C07D487/04 ; C07D487/22 ; C07D498/22 ; A61K31/04 ; A61K31/519 ; A61P29/00 ; A61P25/04 ; A61P25/28 ; A61P35/00 ; C07D487/18 ; C07D498/18

Abstract:
A di(hetero)aryl macrocyclic compound having an inhibitory effect on protein kinase activity, preparation and the use thereof. Specifically, disclosed are a di(hetero)aryl macrocyclic compound represented by formula (I), or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a racemate, a solvate, a hydrate, a polymorph, a prodrug or an active metabolite thereof, a pharmaceutical composition comprising said compound and the derivative thereof, and methods of using the same, including methods of treating cancers, pain, neurological diseases, autoimmune diseases and inflammation.
Public/Granted literature
- US20210171542A1 DI(HETERO)ARYL MACROCYCLIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY Public/Granted day:2021-06-10
Information query